

Advanced Control Formulary®

January 2023 Updates

Removals	Add-Backs
25	10

Removals

Drug Class	Removed Product(s)	Formulary Options
Antiarrhythmics	MULTAQ, NEXTERONE	amiodarone
Anti-Inflammatory, Cryopyrin-Associated Periodic Syndromes (CAPS)	ARCALYST	ILARIS
Asthma, Severe*	NUCALA LYOPHILIZED	DUPIXENT, FASENRA, NUCALA (except lyophilized powder), TEZSPIRE, XOLAIR
Asthma, Steroid/Beta-Agonist Combinations*	ADVAIR HFA	ADVAIR DISKUS, BREO ELLIPTA, SYMBICORT
Asthma, Steroid Inhalants*	ARNUITY ELLIPTA, FLOVENT DISKUS, QVAR REDHALER	FLOVENT HFA, PULMICORT FLEXHALER
Cancer, Antimetabolites	ALIMTA**	pemetrexed
Cancer, Poly-ADP Ribose Polymerase (PARP) Inhibitors	RUBRACA	LYNPARZA, ZEJULA
Cancer, Renal Cell Carcinoma*	SUTENT**, VOTRIENT	sunitinib, CABOMETYX, INLYTA, LENVIMA, NEXAVAR
Diabetes, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors*	JANUMET, JANUMET XR	JENTADUETO, JENTADUETO XR
	JANUVIA	TRADJENTA
Endocrine, Metabolic Modifiers	NITYR	ORFADIN
Hematologic, Hemophilia B*	BENEFIX, IXINITY, RIXUBIS	ALPROLIX, REBINYN
Hereditary Angioedema*	FIRAZYR**	icatibant, RUCONEST
Overactive Bladder, Incontinence Urinary Antispasmodics*	TOVIAZ**	darifenacin ext-rel, oxybutynin ext-rel, solifenacin, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, GEMTESA
Pain & Inflammation, Non-steroidal Anti-Inflammatory Drugs (NSAIDs)*	diclofenac capsule 25 mg	diclofenac sodium, ibuprofen, meloxicam tablet, naproxen (except naproxen CR or naproxen suspension)
	diclofenac solution 2%	diclofenac sodium, diclofenac sodium gel 1%, diclofenac sodium solution 1.5%, ibuprofen, meloxicam tablet, naproxen (except naproxen CR or naproxen suspension)

Drug Class	Removed Product(s)	Formulary Options
Pain, Opioid Analgesics*	NUCYNTA	hydromorphone, morphine, oxycodone
	NUCYNTA ER	fentanyl transdermal, hydrocodone ext-rel, methadone, morphine ext-rel, XTAMPZA ER
	SUBSYS	fentanyl transmucosal
Pulmonary Fibrosis Agents	ESBRIET	pirfenidone, OFEV

Add-Backs

Drug Class	Product(s) Added
Antifungal Agents*	JUBLIA (non-preferred)
Autoimmune Agents*	ILUMYA
Cancer, Follicular Lymphoma PI3K Inhibitors *	ZYDELIG
Diabetes, DPP-4 Inhibitors*	JENTADUETO, JENTADUETO XR, TRADJENTA
Hematologic, Hemophilia B*	ALPROLIX
Menopausal Symptom Agents, Transdermal*	COMBIPATCH
Migraine, Calcitonin Gene-Related Peptide Inhibitors (CGRP) Inhibitors*	AIMOVIG
Parkinson's Disease*	RYTARY
Thrombocytopenia Agents*	MULPLETA (non-preferred)

New to Market Updates

Indication	Product(s) Added
Acne Products*	WINLEVI
Asthma, Severe*	TEZSPIRE
Atopic Dermatitis*	ADBRY, CIBINQO
Cancer, Rearranged During Transfection (RET) Inhibitors	GAVRETO, RETEVMO

Tier 1 Strategy Updates

Tier 1 Brand Formulary Removals	Generic Products Added Back
ASACOL HD	mesalamine delayed-rel tablet 800 mg
ADDERALL XR	amphetamine-dextroamphetamine ext-rel
CONCERTA	methylphenidate ext-rel

Indication-Based Strategy Updates

Indication	Product(s) Added
Ulcerative Colitis	RINVOQ, XELJANZ, XELJANZ XR – Removal of step edit through HUMIRA

*Class has existing formulary exclusions. **Multi-source Brand Product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Removals, Add-Backs and Tier-1 Updates as of September 29, 2022. Information subject to change.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-54612A 092322